India Drug Regulator Takes New Step In Adding To Approval Procedure
This article was originally published in PharmAsia News
Executive Summary
The Drug Controller General of India has selected six laboratories it intends to rely on to test drugs before they are allowed on the Indian market. The DCGI said it is considering the system for making the review process work, including a public-private partnership arrangement. The agency is considering adding the testing procedure instead of relying solely on clinical trial data submitted by drug makers as an additional guarantee of quality. The six government labs have been identified as capable of providing the testing envisioned. (Click here for more
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.